(Q36750849)

16 August 2017

1 reference

title

Microbicide drug candidates to prevent HIV infection (English)

1 reference

16 August 2017

Jan Balzarini

1

1 reference

16 August 2017

Lut Van Damme

series ordinal

2

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 March 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

369

1 reference

16 August 2017

issue

9563

1 reference

16 August 2017

page(s)

787-797

1 reference

Inhibiting sexual transmission of HIV-1 infection

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Microbicides to prevent HIV transmission: overcoming obstacles to chemical barrier protection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Transmission, acute HIV-1 infection and the quest for strategies to prevent infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Repertoire of chemokine receptor expression in the female genital tract: implications for human immunodeficiency virus transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Vaginal CD4+ T cells express high levels of CCR5 and are rapidly depleted in simian immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Viral piracy: HIV-1 targets dendritic cells for transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

A general model for the surface glycoproteins of HIV and other retroviruses.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Infection of dendritic cells (DCs), not DC-SIGN-mediated internalization of human immunodeficiency virus, is required for long-term transfer of virus to T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Candidate microbicides block HIV-1 infection of human immature Langerhans cells within epithelial tissue explants

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Involvement of macrophage mannose receptor in the binding and transmission of HIV by macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Microbicides for prevention of transmission of sexually transmitted diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Anti-HIV-1 microbicides -- 'chemical condoms' designed to limit the scourge of the HIV-1 pandemic.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Brief but efficient: acute HIV infection and the sexual transmission of HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Abnormal vaginal flora as a biological risk factor for acquisition of HIV infection and sexually transmitted diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

In vitro and in vivo: the story of nonoxynol 9.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Clinical microbicide research: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Thermoreversible gel formulations containing sodium lauryl sulfate or n-Lauroylsarcosine as potential topical microbicides against sexually transmitted diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Sodium lauryl sulfate abrogates human immunodeficiency virus infectivity by affecting viral attachment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

The microbicidal agent C31G inhibits Chlamydia trachomatis infectivity in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Safety of single daily use for one week of C31G HEC gel in women.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Microbicides--evaluating multiple formulations of C31G.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Innate antiviral defenses in body fluids and tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Vaginal safety after use of a bioadhesive, acid-buffering, microbicidal contraceptive gel (ACIDFORM) and a 2% nonoxynol-9 product

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Low pH immobilizes and kills human leukocytes and prevents transmission of cell-associated HIV in a mouse model.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Investigating widely available substances as vaginal microbicides

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Novel sulfated polymers as highly potent and selective inhibitors of human immunodeficiency virus replication and giant cell formation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Development of vaginal microbicides for the prevention of heterosexual transmission of HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Cellulose acetate 1,2-benzenedicarboxylate inhibits infection by cell-free and cell-associated primary HIV-1 isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Cellulose acetate phthalate, a common pharmaceutical excipient, inactivates HIV-1 and blocks the coreceptor binding site on the virus envelope glycoprotein gp120

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Anti-HIV-1 activity of anionic polymers: a comparative study of candidate microbicides

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

A novel bacterial mucinase, glycosulfatase, is associated with bacterial vaginosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Papillomavirus microbicidal activities of high-molecular-weight cellulose sulfate, dextran sulfate, and polystyrene sulfonate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Two novel vaginal microbicides (polystyrene sulfonate and cellulose sulfate) inhibit Gardnerella vaginalis and anaerobes commonly associated with bacterial vaginosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Expanded Phase I safety and acceptability study of 6% cellulose sulfate vaginal gel.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Single and multiple exposure tolerance study of cellulose sulfate gel: a Phase I safety and colposcopy study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Anti-HIV activity of extracts and compounds from algae and cyanobacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Carrageenan formulation prevents macrophage trafficking from vagina: implications for microbicide development

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Colposcopic evaluation of a vaginal gel formulation of iota-carrageenan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Safety and acceptability of the candidate microbicide Carraguard in Thai Women: findings from a Phase II Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Direct measurement of in-vivo vaginal microbicide levels of PRO 2000 achieved in a human safety study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Anti-HIV-1 activity of cellulose acetate phthalate: synergy with soluble CD4 and induction of "dead-end" gp41 six-helix bundles

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Cellulose acetate 1,2-benzenedicarboxylate protects against challenge with pathogenic X4 and R5 simian/human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Multiple vaginal exposures to low doses of R5 simian-human immunodeficiency virus: strategy to study HIV preclinical interventions in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Safety and distribution of cellulose acetate 1,2-benzenedicarboxylate (CAP), a candidate anti-HIV microbicide in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

A humanized, nondepleting anti-CD4 antibody that blocks virus entry inhibits virus replication in rhesus monkeys chronically infected with simian immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Cyclotriazadisulfonamides: promising new CD4-targeted anti-HIV drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

HIV-1 entry inhibitors: new targets, novel therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

HIV entry inhibitors in clinical development

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

HIV chemokine receptor inhibitors as novel anti-HIV drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Combination of CCR5 and CXCR4 inhibitors in therapy of human immunodeficiency virus type 1 infection: in vitro studies of mixed virus infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Diversity of receptors binding HIV on dendritic cell subsets

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Human immunodeficiency virus envelope (gp120) binding to DC-SIGN and primary dendritic cells is carbohydrate dependent but does not involve 2G12 or cyanovirin binding sites: implications for structural analyses of gp120-DC-SIGN binding

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

gp120: Biologic aspects of structural features

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Targeting the glycans of gp120: a novel approach aimed at the Achilles heel of HIV

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Carbohydrate-binding Agents Cause Deletions of Highly Conserved Glycosylation Sites in HIV GP120

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissocia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Antibody domain exchange is an immunological solution to carbohydrate cluster recognition

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

The microbicide cyanovirin-N expressed on the surface of commensal bacterium Streptococcus gordonii captures HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

An anti-HIV microbicide comes alive

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Toward a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Development of HIV fusion inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

In vitro microbicidal activity of the nonnucleoside reverse transcriptase inhibitor (NNRTI) UC781 against NNRTI-resistant human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Blocking of cell-free and cell-associated HIV-1 transmission through human cervix organ culture with UC781.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Dawn of non-nucleoside inhibitor-based anti-HIV microbicides

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Considerations and development of topical microbicides to inhibit the sexual transmission of HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Emerging drug targets for antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Will microbicide trials yield unbiased estimates of microbicide efficacy?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

Assay for establishing whether microbicide applicators have been exposed to the vagina.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

HIV prevention research in a resource-limited setting: the experience of planning a trial in Cambodia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

The abandoned trials of pre-exposure prophylaxis for HIV: what went wrong?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960202-5

7 January 2021

10.1016/S0140-6736(07)60202-5

Identifiers

DOI

1 reference

16 August 2017

1 reference